YS Biopharma Co., Ltd. announced its PIKA Rabies Vaccine has received Phase 3 clinical trial approval from the Drug Regulatory Authority of Pakistan ("DRAP"). The Phase 3 clinical trial will evaluate the safety and immunogenicity of the Company's PIKA Rabies Vaccines in preventing rabies infection. The PIKA Rabies vaccine is a novel vaccine powered by YS Biopharma's proprietary PIKA adjuvant technology to reduce accelerated immunity and produce a higher immune response.

The PIKA Rabie Vaccine has the potential to become the first accelerated three-visit one-week regimen, superior to the currently available vaccine with a five-visit one-month or three-visit three-week regimen. The Company has completed Phase 1 and Phase 2 clinical trials of its PIKA Rabies vaccine in Singapore. Another Phase 1 trial was also conducted in China to confirm the optimum dose and regimen to be used.

All three clinical trials have shown that the PIKA rabies vaccine is safe, tolerable, and immunogenic. YS Biopharma has also obtained approval to conduct Phase 3 clinical trials of the PIKA Rabies vaccine In Singapore. The Phase 3 study is a multi-center, multi-country study set to be conducted in Singapore, the Philippines, and Pakistan in 2023.

YS Biopharma anticipates conducting Phase 3 clinical trials in healthy volunteers without exposure to animal bites, with an estimated 4,500 subjects in total. The Company is also planning to conduct more advanced clinical trials in China. Pending the successful completion of Phase 3 trials, the Company intends to submit the New Drug Application or Biologics License Application for the PIKA Rabies VaccINE to regulatory authorities in China and countries in Asia and other continents.